Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Whoosh plans to allocate ₽1.14 billion to dividends

9/28/23 WUSH

VTB accrued additional provisions due to a large credit loss

9/28/23 VTBR

TMK sold its scrap procurement division

9/28/23 TRMK

Moscow Exchange aims to increase net profit to ₽65 billion by 2028

9/28/23 MOEX

VTB reported 8 months of 2023 by IFRS

9/28/23 VTBR

Moscow Exchange will allocate to dividends at least 50% of profit

9/28/23 MOEX

Lukoil may retain the right to handle Russian oil in Bulgaria for one year

9/28/23 LKOH

Vgudok named the sale price of UWC

9/28/23 UWGN

Sistema sold the venture fund Sistema SmartTech

9/28/23 AFKS

Positive Technologies SPO participants acquired 205 thousand additional shares

9/28/23 POSI